Uncategorised - European Medical Journal

Rafael Fonseca

Hema Now: Episode 18: Myeloma Genetics, CAR-T, and Emerging Immunotherapies

Rafael Fonseca, Consultant, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA

AI Tool Accurately Predicts Liver Graft Injury Causes

The model analyses demographic information, lab results, and other clinical data to predict the cause of graft injury across six possible conditions.

Rising Threat: Candida Eye Infections Demand Urgent Action

Candida endophthalmitis and chorioretinitis, sight-threatening complications of candidemia, are on the rise and require faster, more coordinated care, according to a recent review.

Immunoglobulin Therapy Slows Kidney Decline in Chronic Rejection, Trial Finds

In a landmark trial, IVIG therapy was shown to slow kidney function decline and tissue damage in patients with chronic active antibody-mediated rejection.

High-Flow Oxygen Shows Limited Benefit in Paediatric Intubation

A major international trial has assessed whether nasal high-flow oxygen improves outcomes during emergency paediatric intubation.

ERA 2025: New Biomarker Model Predicts Kidney Fibrosis in IgA Nephropathy

Selected as a top 10 abstract at the ERA Congress, this study unveils a new multiple biomarker model to predict tubulointerstitial fibrosis in IgA nephropathy without a biopsy.

Respiratory Microbiota Shifts with COVID-19 Severity Progression

New research reveals that the composition of the lower respiratory tract microbiota is closely linked to COVID-19 severity.

How Four Botox Options Differ for Frown Lines

The findings highlight that abobotulinum toxin A and prabotulinum toxin A demonstrated the quickest onset of action.

Bradykinin and Angioedema

Angioedema (AE) syndromes are associated with recurrent, unpredictable attacks of subcutaneous and submucosal tissue swelling, which can…

Rheumatoid Arthritis Raises Tuberculosis Risk Despite Screening

In a major new study of over 350,000 individuals, researchers have uncovered compelling evidence that patients with rheumatoid arthritis face a significantly higher risk of developing active pulmonary tuberculosis, even in modern healthcare settings where tuberculosis screening precedes biologic treatment.